PURPOSE: The purpose of this study is to demonstrate the long-term, controlled, zero-order release of low- and high-molecular weight chemotherapeutics through nanochannel membranes by exploiting the molecule-to-surface interactions presented by nanoconfinement. METHODS: Silicon membranes were produced with nanochannels of 5, 13 and 20 nm using standardized industrial microfabrication techniques. The study of the diffusion kinetics of interferon α-2b and leuprolide was performed by employing UV diffusion chambers. The released amount in the sink reservoir was monitored by UV absorbance. RESULTS: Continuous zero-order release was demonstrated for interferon α-2b and leuprolide at release rates of 20 and 100 μg/day, respectively. The release rates exhibited by these membranes were verified to be in ranges suitable for human therapeutic applications. CONCLUSIONS: Our membranes potentially represent a viable nanotechnological approach for the controlled administration of chemotherapeutics intended to improve the therapeutic efficacy of treatment and reduce many of the side effects associated with conventional drug administration.
PURPOSE: The purpose of this study is to demonstrate the long-term, controlled, zero-order release of low- and high-molecular weight chemotherapeutics through nanochannel membranes by exploiting the molecule-to-surface interactions presented by nanoconfinement. METHODS:Silicon membranes were produced with nanochannels of 5, 13 and 20 nm using standardized industrial microfabrication techniques. The study of the diffusion kinetics of interferon α-2b and leuprolide was performed by employing UV diffusion chambers. The released amount in the sink reservoir was monitored by UV absorbance. RESULTS: Continuous zero-order release was demonstrated for interferon α-2b and leuprolide at release rates of 20 and 100 μg/day, respectively. The release rates exhibited by these membranes were verified to be in ranges suitable for human therapeutic applications. CONCLUSIONS: Our membranes potentially represent a viable nanotechnological approach for the controlled administration of chemotherapeutics intended to improve the therapeutic efficacy of treatment and reduce many of the side effects associated with conventional drug administration.
Authors: J C Wright; S Tao Leonard; C L Stevenson; J C Beck; G Chen; R M Jao; P A Johnson; J Leonard; R J Skowronski Journal: J Control Release Date: 2001-07-10 Impact factor: 9.776
Authors: Frank Martin; Robbie Walczak; Anthony Boiarski; Michael Cohen; Teri West; Carlo Cosentino; John Shapiro; Mauro Ferrari Journal: J Control Release Date: 2005-01-20 Impact factor: 9.776
Authors: L Tamayo; D M Ortiz; L Orozco-Covarrubias; C Durán-McKinster; M A Mora; E Avila; F Teixeira; R Ruiz-Maldonado Journal: Arch Dermatol Date: 1997-12
Authors: Maria P Brizzi; Alfredo Berruti; Anna Ferrero; Enrica Milanesi; Marco Volante; Federico Castiglione; Nadia Birocco; Sebastiano Bombaci; Davide Perroni; Benedetta Ferretti; Oscar Alabiso; Libero Ciuffreda; Oscar Bertetto; Mauro Papotti; Luigi Dogliotti Journal: BMC Cancer Date: 2009-11-03 Impact factor: 4.430
Authors: Christian Celia; Silvia Ferrati; Shyam Bansal; Anne L van de Ven; Barbara Ruozi; Erika Zabre; Sharath Hosali; Donatella Paolino; Maria Grazia Sarpietro; Daniel Fine; Massimo Fresta; Mauro Ferrari; Alessandro Grattoni Journal: Adv Healthc Mater Date: 2013-07-23 Impact factor: 9.933
Authors: Daniel Fine; Alessandro Grattoni; Randy Goodall; Shyam S Bansal; Ciro Chiappini; Sharath Hosali; Anne L van de Ven; Srimeenkashi Srinivasan; Xuewu Liu; Biana Godin; Louis Brousseau; Iman K Yazdi; Joseph Fernandez-Moure; Ennio Tasciotti; Hung-Jen Wu; Ye Hu; Steve Klemm; Mauro Ferrari Journal: Adv Healthc Mater Date: 2013-04-15 Impact factor: 9.933
Authors: C S Filgueira; E Nicolov; R L Hood; A Ballerini; J Garcia-Huidobro; J Z Lin; D Fraga; P Webb; O M Sabek; A O Gaber; K J Phillips; A Grattoni Journal: Int J Obes (Lond) Date: 2016-07-27 Impact factor: 5.095
Authors: Ennio Tasciotti; Fernando J Cabrera; Michael Evangelopoulos; Jonathan O Martinez; Usha R Thekkedath; Malgorzata Kloc; Rafik M Ghobrial; Xian C Li; Alessandro Grattoni; Mauro Ferrari Journal: Transplantation Date: 2016-08 Impact factor: 4.939